247 results
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
7 Mar 24
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
4:10pm
Securities Litigation Reform Act of 1995.
Contact Information:
Investors
Richard Vincent
858-434-1113
rvincent@oncternal.com
Media
Corey Davis, Ph.D
8-K
zkl9 gtz2
5 Jan 24
Results of Operations and Financial Condition
4:00pm
8-K
EX-99.1
pljj5k0t1s4fhdtzt
9 Nov 23
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
4:15pm
8-K
EX-99.1
1n1prdrp01g0jhvuv
10 Aug 23
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results
4:11pm
8-K
EX-99.1
25hli oie9zy6foie39
4 May 23
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
4:10pm
8-K
irgyi
3 Apr 23
Results of Operations and Financial Condition
4:20pm
8-K
EX-99.1
r22aczqh
3 Nov 22
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results
4:17pm
8-K
0ay n7f87vj9d6j92f5n
3 Oct 22
Results of Operations and Financial Condition
4:46pm
8-K
EX-99.1
ygyh 0hi3xg
5 May 22
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results
12:00am